'Pk studies' presentation slideshows

Company Introduction

Company Introduction. THE FRONTAGE ADVANTAGE. Attention, Efficiency, and Expertise. Who is Frontage Laboratories?. We are an early phase drug development company Started in 2002 Currently 225 people We have grown organically and through acquisition (clinical)

782 views • 55 slides

PK / inhibitors: how to interpret in hemophilia

PK / inhibitors: how to interpret in hemophilia. Alfonso Iorio, MD PhD McMaster University, Canada. Alfonso Iorio MD, PhD, FRCPC Professor of Medicine McMaster University. Disclosures

403 views • 40 slides

Pediatric Clinical Trials at the National Institutes of Health

Pediatric Clinical Trials at the National Institutes of Health. Anne Zajicek, MD, PharmD Obstetric and Pediatric Pharmacology Branch Center for Research for Mothers and Children National Institute of Child Health and Human Development, NIH. Outline. ClinicalTrials.gov listings

449 views • 29 slides

Special Issues in Development of CNS Active Drugs

Special Issues in Development of CNS Active Drugs. Nimita Dave, Ph.D. 04/03/13. Barriers/Challenges Examples Techniques to Study Brain Pharmacokinetics Brain Tumors Our Findings (Letrozole). Outline. Brain injury CNS Infections Epilepsy

422 views • 26 slides

Systemic Exposure of Topical Tacrolimus

Systemic Exposure of Topical Tacrolimus. Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology and Biopharmaceutics. Adult PK Studies In NDA. In healthy volunteers (N=12)

254 views • 13 slides

Summary of PK studies thru 10/1/04*

Summary of PK studies thru 10/1/04*. * Samples analyzed thru 5/30/04. Immunosuppressant doses and Cmin after 2-4 weeks of rx. 350. 300. Wk 2. Wk 12. Wk 28. Yr 1. Yr 2. 250. 200. 150. CsA mg/dose. 100. 50. 0. NVP. EFV. 1 PI. 2 PI. kaletra. NNRTI. NNRTI +. +PI . kaletra.

158 views • 6 slides

Methods

203 views • 1 slides